sustained mrd negativity in mm with lenalidomide maintenance
Published 4 years ago • 56 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
1:21
the value of sustained mrd negativity in mm
-
0:55
sustained mrd negativity in multiple myeloma
-
0:47
sustained mrd for treatment guidance in myeloma
-
2:20
the immune microenvironment predicts sustained mrd-negativity after d-krd treatment for myeloma
-
1:10
should we adapt treatment based on mrd status in mm?
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
3:52
blood volume monitoring using crit-line® technology
-
1:35:54
the future is now in mds: integrating innovative, risk-adapted therapies into patient management
-
2:31
evaluating the safety of maintenance therapy cessation in mrd negative myeloma patients
-
2:05
using mrd negativity to measure depth of response & to discontinue treatment in multiple myeloma
-
1:25
lenalidomide maintenance remains best for newly diagnosed mm
-
8:40
lenalidomide, mutations & mds outcomes
-
1:36
the importance of mrd as a prognostic tool in multiple myeloma
-
3:27
mrd negativity using deep sequencing is a major prognostic factor in myeloma
-
3:05
mrd negativity assessed by flow cytometry associated with improved outcomes in npm1-mutated aml
-
8:42
assessing mrd in multiple myeloma
-
2:23
the use of immunophenotyping to assess minimal residual disease (mrd) in multiple myeloma
-
1:21
vrd induction, mel200-conditioned autohsct and lenalidomide maintenance in multiple myeloma
-
2:18
new applications for mrd measurement in myeloma: mrd 'over time'
-
2:25
expanding role for mrd in managing mm
-
3:22
the main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
-
2:57
when is the optimal time to measure minimal residual disease (mrd) in myeloma patients?